REBEC

Public trial

Effects of Protein supplementation on body composition, handshake strength and quality of life of patients undergoing Spine surgery

Date of registration: 02/02/2021 ^(mm/dd/yyyy)
Last approval date : 07/15/2024 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Pharmacological Therapy for the treatment of Obstructive Sleep Apnea: a randomized clinical trial

Date of registration: 07/15/2024 ^(mm/dd/yyyy)
Last approval date : 07/15/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Use of Myoinositol in patients with Polycystic Ovary Syndrome who will undergo a procedure to try to get pregnant

Date of registration: 07/15/2024 ^(mm/dd/yyyy)
Last approval date : 07/15/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of Light Therapy and Manual Manipulation Technique on improving physical capacity and reducing pain in adults subjected to Muscle Damage

Date of registration: 07/15/2024 ^(mm/dd/yyyy)
Last approval date : 07/15/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Impact of physical exercise on heart and skeletal muscle health

Date of registration: 07/12/2024 ^(mm/dd/yyyy)
Last approval date : 07/12/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Implementation and effectiveness of an Integrative Practice Protocol as an aid to common treatment in reducing symptoms of Depression for patients in primary health care

Date of registration: 07/11/2024 ^(mm/dd/yyyy)
Last approval date : 07/11/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of Non-Invasive Neuromodulation in improving balance and gait of individuals with Parkinson´s disease

Date of registration: 08/26/2022 ^(mm/dd/yyyy)
Last approval date : 07/09/2024 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Evaluation of heated anesthetic during anesthesia in children

Date of registration: 07/09/2024 ^(mm/dd/yyyy)
Last approval date : 07/09/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Use of the Placental Growth Factor (PlGF) test in pregnant women with Chronic Hypertension to evaluate superimposed Pre-eclampsia

Date of registration: 07/09/2024 ^(mm/dd/yyyy)
Last approval date : 07/09/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Evaluation of Photobiomodulation in topical anesthetic absorption and pain reduction during Local Infiltrative Anesthesia

Date of registration: 07/09/2024 ^(mm/dd/yyyy)
Last approval date : 07/09/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Clinical evaluation of Prostheses on implants installed by different techniques (Guided and Conventional)

Date of registration: 02/18/2023 ^(mm/dd/yyyy)
Last approval date : 07/09/2024 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Effect of Time Under Tension in Recreational Runners

Date of registration: 07/08/2024 ^(mm/dd/yyyy)
Last approval date : 07/08/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

The tactical performance of football players under Cerebral Stimulation

Date of registration: 07/08/2024 ^(mm/dd/yyyy)
Last approval date : 07/08/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Development of new rehabilitation methods to recovery post-stroke patients

Date of registration: 07/06/2024 ^(mm/dd/yyyy)
Last approval date : 07/06/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effects of a training protocol for breathing musculature in patients undergoing coronary artery bypass grafting

Date of registration: 05/02/2018 ^(mm/dd/yyyy)
Last approval date : 07/05/2024 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Psychological intervention pProtocol for promoting Healthy Ageing

Date of registration: 07/04/2024 ^(mm/dd/yyyy)
Last approval date : 07/04/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of Osteopathy in individuals with Reflux of stomach contents into the esophagus on quality of life and on the surface temperature of the thoracic region

Date of registration: 07/04/2024 ^(mm/dd/yyyy)
Last approval date : 07/04/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Success of Restorations of Milk Teeth with Glass Ionomer without using Polyacrylic Acid and with the use of Acid - Study with 2 Years Follow-up

Date of registration: 06/01/2023 ^(mm/dd/yyyy)
Last approval date : 07/03/2024 ^(mm/dd/yyyy)
Last revision: 2

Study type:

Interventional

Open bite treatment with fixed palatal crib with and without myofunctional therapy: a randomized clinical trial

Date of registration: 07/03/2024 ^(mm/dd/yyyy)
Last approval date : 07/03/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Effect of beetroot juice ingestion on strength

Date of registration: 07/03/2024 ^(mm/dd/yyyy)
Last approval date : 07/03/2024 ^(mm/dd/yyyy)
Last revision: 1

Study type:

Interventional

Username/Password

News

10/03/2025

How Government Shutdowns Set Back Clinical Trials

10/03/2025 | Denise N. Bronner | Clinical Leader

https://www.clinicalleader.com/doc/how-government-shutdowns-set-back-clinical-trials-0001

When the federal government shuts down, news coverage tends to spotlight furloughed workers, frozen paychecks, or the political drama playing out in Washington. What gets less attention is how these lapses stall the engine of scientific progress. For clinical research, even a brief shutdown can trigger cascading consequences: disrupted operations, wavering patient participation, delayed approvals, and setbacks for urgently needed therapeutics.

Clinical research thrives on continuity. It is built on tightly orchestrated timelines, fragile patient trust, and a steady flow of regulatory and financial resources. When that continuity is interrupted, the ripple effects extend far beyond missed deadlines. They reach the lives of patients who depend on trials for care and the future of therapies waiting to move from pipeline to practice.

Regulatory Bottlenecks & Uncertainty
The FDA sits at the center of clinical research, reviewing new drug applications, monitoring safety, and ensuring compliance. A shutdown leaves the agency with only a skeleton crew. Historically, about one-third of FDA staff have been furloughed during extended shutdowns, forcing the Agency to pause most routine operations. New drug and device submissions may be accepted, but reviews stall. Site inspections and audits, critical for moving programs forward, are postponed. And sponsors often find their regulatory queries met with silence.

These delays may seem procedural, but they create real-world consequences. A biotech preparing to launch a pivotal trial might suddenly find its timeline upended. A CRO monitoring multiple sites may have to cancel visits, raising questions…

10/01/2025

Enactment of Law No. 14,874 ushers in a new era of clinical research

09/29/2025 | Fernando de Rezende Francisco | Medicina S/A

https://medicinasa.com.br/sancao-lei-14-874-2024/

Brazil has begun a new chapter in Clinical Research with the enactment of Law No. 14,874/2024, which establishes a robust and modern regulatory framework in line with international best practices. More than just updating standards, the law creates conditions to expand the population's access to studies that bring innovation, new therapies, and a better quality of life.

Although the legislative process took almost a decade, the most recent stage of this process was marked by the leading role played by the Ministry of Health, through the Secretariat of Science, Technology, Innovation, and Health Complex (SECTICS) and the Department of Science and Technology (DECIT). In recent months, these areas have taken the lead on the agenda, competently and dialogically conducting the process that will culminate in the beginning of the regulation of the law and the reorganization of the ethical research system.

Despite its enormous potential, Brazil participates in just over 1% of global clinical studies, according to ClinicalTrials.gov. This means less investment, less access to cutting-edge technologies, and fewer opportunities for patients. Law No. 14,874/2024 paves the way for changing this scenario, and the recent actions of the Ministry of Health are decisive in consolidating these transformations.

The movement to draft a law for this area gained momentum in 2014 when Afonso Celso Haas, a businessman from Rio Grande do Sul diagnosed with advanced lung cancer, found a chance to prolong his life in a clinical trial. The experimental treatment not only gave him five additional years with his family, but also turned him into a symbol of the fight for the modernization of the sector.

Inspired by his story, doctors, lawmakers, organizations, and civil society…

10/01/2025

Law 14.874/24: a new perspective for clinical research in Brazil

10/01/2025 | Eurico Bitencourt Neto, Brunello Stancioli | Jota

https://www.jota.info/opiniao-e-analise/artigos/lei-14-874-24-uma-nova-perspectiva-para-a-pesquisa-clinica-no-brasil

Legislation is welcome and represents a bioethical and administrative milestone for Brazilian research

Improvements in the health, well-being, and productivity of contemporary societies are largely linked to advances in biomedical research and the improvements they bring to collective and individual health. In an era marked by exponential production of information and knowledge and, at the same time, by growing uncertainty and risk, biomedical sciences play a central role as a tool that saves lives and prevents disease in a world that still grapples with profound inequalities, thus serving as an important instrument of social justice.

In this context of undeniable relevance, the progress of biomedical research involves a double ethical challenge. On the one hand, preventing or hindering scientific research means hindering prophylaxis, cure, and prevention for countless diseases, hindering the achievement of better health conditions and adequate care for those facing various causes of suffering. On the other hand, clinical research involves the participation of volunteers who agree to subject themselves to certain risks in order for scientific progress to be achieved, which requires a protection system that ensures the preservation of their fundamental rights of personality.

Ensuring the ethics of research and the safety and interests of research participants is fundamental in this process, as they are the key to the tests that culminate in scientific advancement. However, until last year, Brazil offered very fragile legal guarantees to research participants.

Research ethics standards in Brazil…

09/30/2025

Age Diversity In Clinical Trials: Considerations For Improving Older Adult Representation

09/30/2025 | Nick Charron and Hannah Yang | Clinical Leader

https://www.clinicalleader.com/doc/age-diversity-in-clinical-trials-considerations-for-improving-older-adult-representation-0001

The share of the U.S. population aged 65 and older grew to 18% in 2024,1 now outnumbering children in nearly half of the country's counties. These demographic shifts are expected to continue, with estimates stating that the global population above 60 will double by 2050.2

It’s crucial to understand how these trends impact clinical trials,3 where older adults have historically been underrepresented. For several large oncology indications, the enrollment-to-incidence ratio (EIR) is only 25% for those above 70,4 revealing a significant discrepancy in inclusion.

Without prioritizing DEI, research findings aren’t fully generalizable5 to this key demographic, limiting the applicability of trials. In this piece, we dive into the importance of age diversity in clinical trials, breaking down innovative methods to redesign clinical trials and better engage older populations in the U.S.

Implications Of Underrepresenting Older Adults In Clinical Trials
Despite the shifting demographics of the U.S. population, only 50%6 of clinical trials specifically enroll patients under the age of 65, and 8% of trials enroll patients 80 and older. Many clinical trials also exclude older adults with comorbidities,7 further limiting their relevance to real-world populations.

While it’s true that comorbidities can complicate trial results and risk jeopardizing approval of a viable therapy, overly stringent inclusion/exclusion (I/E) criteria unnecessarily restrict participation. This exclusion creates a gap in data8 on efficacy and safety of treatments…

09/30/2025

Mobilisers on Motorbikes: The Complex Process of Involving Communities in Clinical Trials

09/29/2025 | Kerry Cullinan | Health Policy Watch

https://healthpolicy-watch.news/mobilisers-on-motorbikes-the-complex-process-of-involving-communities-in-clinical-trials/

Recruiting semi-nomadic people from West Pokot, Kenya, in a clinical trial meant those running the trial needed to know where to find them when they went in search of water and grazing for their animals.

Engaging people from a nomadic community in rural Kenya in a clinical trial involved employing community mobilisers on motorbikes and understanding seasonal and cultural practices.

Geographic touchpoints such as waterholes and schools were mapped as places to find trial participants as they searched for grazing and water for their cattle and goats.

This was a lot of work, but for Luke Kanyangareng, a nurse based in rural West Pokot, adjacent to the Ugandan border, the community is the main stakeholder in clinical trials.

“Clinical trials are about getting a solution to their health problems, so we need to recruit and keep rural patients in the trial,” said Kanyangareng, who recently won an international award for his role as a patient advocate.

“Understanding their life setup is also very important, because when you are doing recruitment, you should know where this patient is coming from, and where you expect to find this patient at different seasons of the year.”

Kanyangareng was addressing a September 16 webinar on patient and community engagement in clinical trials. The webinar, hosted by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) was the first such event in a series of four, comprising this year’s African Regulatory Conference. The online conference focused…